^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
Source:
Title:
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Excerpt:
...- Participant must have a documented RET-fusion...
Trial ID:
Source:
Title:
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Excerpt:
...- participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion previously treated with a platinum-based chemotherapy....
Trial ID:
More C2 evidence
Source:
Title:
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Excerpt:
...- Must have a diagnosis of locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC...
Trial ID:
Source:
Title:
A study of BLU-667 in patients with lung cancer
Excerpt:
...Patient must meet 1 of the following 2 criteria: a. Have a documented RET fusion using either tissue or plasma as determined by a local test. ...
Trial ID:
Source:
Title:
A Phase 1 Study of the Highly-Selective RET Inhibitor, BLU 667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Excerpt:
...Diagnosis during dose expansion (Part 2) – All patients (with the exception of Groups 3, 4 and 9) must have an oncogenic RET fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local or central testing of tumor or circulating tumor nucleic acid in blood; as detailed below. ...
Trial ID:
Source:
Title:
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Excerpt:
...Pathologically documented and definitively diagnosed non-resectable or metastatic NSCLC with a RET fusion for patients who are either treatment naïve, or who have been previously treated with systemic therapy....
Trial ID:
Source:
Title:
A study of BLU-667 in patients with lung cancer, and thyroid cancer, and other solid tumors
Excerpt:
...Diagnosis during dose expansion (Phase 2) – All patients (with the exception of patients with MTC enrolled in Groups 3, 4 and 9) must have an oncogenic RET fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local testing of tumor or circulating tumor nucleic acid in blood; as detailed below. ...
Trial ID:
Less C2 evidence
Source:
Title:
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Published date:
08/12/2022
Excerpt:
ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors...Median duration of response, progression-free survival and overall survival were 12 months, 7 months and 14 months, respectively.
DOI:
10.1038/s41591-022-01931-y
Trial ID:
